Longhorn was founded and is led by Gerald Fischer, MD. He has been developing diagnostic technologies and therapuetics for over 35 years, for both the US Army and commercial applications. Dr. Fischer and two colleagues discovered, developed, and licensed anti-RSV antibody technology to Medimmune and provided key pre-clinical development support. The products that were commercialized from that technology include Respigam and Synagis. Together those products have generated over $10 billion worldwide and continue to generate sales of $1 billion annually.
To harness the power of molecular biology, Longhorn utilizes multiple molecular techniques to improve and expand our capabilities to diagnose, prevent and treat diseases that affect people across the globe. Corporate offices are located in Bethesda, Maryland with Molecular Biology labs in San Antonio, Texas and Vaccine and Immunology labs in Rockville, Maryland.
The molecular biology lab is focused on developing, testing and deploying molecular diagnostic products to identify and characterize important cellular and microbial nucleic acid sequences, genes and genomes. Current products include PrimeStore a molecular collection, preservation and transport media and PrimeMix an all inclusive, temperature stable PCR detection reagent. These products are deployed across the world for surveillance and diagnosis of viral respiratory infections and tuberculosis. The team has worked closely with prominent scientists in South Africa to systematically, over the last four years, to develop and test PrimeSuite TB. New products to include PrimeXtract and PrimeSeq facilitate and improve nucleic acid, gene and whole genomic identification and characterization.
The vaccine and immunology lab is focused on leveraging our molecular biology capabilities to develop new technologies to improve the prevention and treatment of animal and human diseases. The initial focus is on Influenza and Tuberculosis vaccines and therapeutics. Several early phase products are in in vitro analysis and we anticipate that selected candidates will move toward in vivo testing in the near horizon.